Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Calcitonin Salmon Market : Size, Application Analysis, Regional Outlook, 2016 - 2026

Author: Sneha Talankar
by Sneha Talankar
Posted: Jan 05, 2019

Calcitonin, also called thyrocalcitonin, is a linear polypeptide hormone produced in human thyroid glands by parafollicular cells. In fish, birds, and other non-mammalian animals, calcitonin is produced by cells of ultimobranchial body. Calcitonin lowers the levels of calcium and phosphate in blood and promotes the bone formation. Calcitonin inhibits the bone removal cells called osteoclasts and simultaneously promotes bone formation cells called osteoblasts. The potency of calcitonin salmon per mg is greater and has longer duration of action than calcitonin produced by mammalian origin.

Read Report Overview: https://www.transparencymarketresearch.com/calcitonin-salmon-market.html

Calcitonin salmon is produced either by synthetic processes or by microbial processes using recombinant DNA technology. Calcitonin salmon is available in two forms: injection and nasal. Miacalcin and Fortical are commonly available brands for calcitonin salmon. Calcitonin salmon is used for indications such as osteoporosis, hypercalcemia, Paget’s disease of bone, and other bone related diseases.

The global calcitonin salmon market is driven by increasing number of osteoporosis patients globally. According to the International Osteoporosis Foundation, over 8.9 million people suffer from osteoporosis globally each year. Osteoporosis is more dominant in women than men and is common in geriatric population. The International Osteoporosis Foundation study reveals that over 200 million women are affected by osteoporosis globally. The FDA advisory committee has recommended to prevent use of calcitonin salmon for the treatment of postmenstrual osteoporosis in women as there exists a potential risk of cancer development. Moreover, calcitonin salmon is used as second line of treatment for osteoporosis. Side effects of calcitonin salmon are likely to be key restraints of the global market. Large number of people are not aware about having osteoporosis until they have first fracture and also Paget’s disease is not common in people. These factors hamper the growth of the calcitonin salmon market. Easy availability of other medications for the first line treatment of osteoporosis and related diseases is likely to restrain the market. The FDA advisory committee has suggested to companies developing new calcitonin salmon products to prove its effectiveness in reducing bone fractures. This is expected to boost the market.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19730

The global calcitonin salmon market has been segmented based on route of administration and type of indication. Calcitonin salmon can be administered through injection or by nasal spray. The calcitonin nasal spray is indicated for patients for whom alternative treatments are not suitable. Calcitonin injections are used for the treatment of Paget’s disease of bone and hypercalcemia. It can be administered through subcutaneous, intramuscular, and intranasal routes. Calcitonin salmon is used for the treatment of osteoporosis, Paget’s disease, and hypercalcemia.

Geographically, the global calcitonin salmon market has been segmented into five regions: North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Over 75 million people are estimated to be affected by osteoporosis in the U.S., Europe, and Japan. This highlights the growth opportunity in these regions. Prevalence of osteoporosis is higher in Middle East & Africa than in countries in the West. This is expected to propel the calcitonin salmon market in this region. Increasing geriatric population with bone related diseases is likely to fuel the growth of the market in Asia Pacific during the forecast period.

Request For TOC : https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=19730

Key players in the calcitonin salmon market include Novartis AG, Apotex, Inc., Upsher-Smith Laboratories, Inc., Alkem Laboratories Ltd., Torrent Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., and United Biotech (P) Limited.

Novartis AG, Upsher-Smith Laboratorie, Inc., and Torrent Pharmaceuticals are the leading players in the global calcitonin salmon market.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

About the Author

Transparency Market Research (Tmr) is a U.S.-based provider of syndicated research, customized research, and consulting services.

Rate this Article
Leave a Comment
Author Thumbnail
I Agree:
Comment 
Pictures
Author: Sneha Talankar

Sneha Talankar

Member since: May 10, 2018
Published articles: 1372

Related Articles